{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:25:46Z","timestamp":1773422746358,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40257-022-00722-y","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T10:04:16Z","timestamp":1660730656000},"page":"891-904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Drug Survival of Interleukin (IL)\u201117 and IL\u201123 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi\u2011country, Multicentric Cohort Study"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[]},{"given":"Ron","family":"Vender","sequence":"additional","affiliation":[]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9-Manuel","family":"Carrascosa","sequence":"additional","affiliation":[]},{"given":"Stefano","family":"Piaserico","sequence":"additional","affiliation":[]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Pedro Mendes","family":"Bastos","sequence":"additional","affiliation":[]},{"given":"Esteban","family":"Dauden","sequence":"additional","affiliation":[]},{"given":"Luiz","family":"Leite","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Valerio","sequence":"additional","affiliation":[]},{"given":"Elena","family":"del Alc\u00e1zar-Viladomiu","sequence":"additional","affiliation":[]},{"given":"Eva Vilarrasa","family":"Rull","sequence":"additional","affiliation":[]},{"given":"Mar","family":"Llamas-Velasco","sequence":"additional","affiliation":[]},{"given":"Federico","family":"Pirro","sequence":"additional","affiliation":[]},{"given":"Francesco","family":"Messina","sequence":"additional","affiliation":[]},{"given":"Manfredo","family":"Bruni","sequence":"additional","affiliation":[]},{"given":"Gaetano","family":"Licata","sequence":"additional","affiliation":[]},{"given":"Federica","family":"Ricceri","sequence":"additional","affiliation":[]},{"given":"Alessia","family":"Nidegger","sequence":"additional","affiliation":[]},{"given":"Jan","family":"Hugo","sequence":"additional","affiliation":[]},{"given":"Asfandyar","family":"Mufti","sequence":"additional","affiliation":[]},{"given":"Athina-Ioanna","family":"Daponte","sequence":"additional","affiliation":[]},{"given":"Laetitia","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[]},{"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[]},{"given":"Spyridon","family":"Gkalpakiotis","sequence":"additional","affiliation":[]},{"given":"Curdin","family":"Conrad","sequence":"additional","affiliation":[]},{"given":"Elizabeth","family":"Lazaridou","sequence":"additional","affiliation":[]},{"given":"Natalia","family":"Rompoti","sequence":"additional","affiliation":[]},{"given":"Marina","family":"Papoutsaki","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Nogueira","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"issue":"19","key":"722_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/JAMA.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/JAMA.2020.4006.","journal-title":"JAMA"},{"issue":"5","key":"722_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17512433.2020.1767590","volume":"13","author":"Y-C Tsai","year":"2020","unstructured":"Tsai Y-C, Tsai T-F. Switching biologics in psoriasis\u2014practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493\u2013503. https:\/\/doi.org\/10.1080\/17512433.2020.1767590.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1\u20132","key":"722_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000488586","volume":"234","author":"A Costanzo","year":"2018","unstructured":"Costanzo A, Malara G, Pelucchi C, et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology. 2018;234(1\u20132):1\u201312. https:\/\/doi.org\/10.1159\/000488586.","journal-title":"Dermatology"},{"issue":"7","key":"722_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/JID.2015.171","volume":"135","author":"JMPA van den Reek","year":"2015","unstructured":"van den Reek JMPA, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Investig Dermatol. 2015;135(7):1\u20135. https:\/\/doi.org\/10.1038\/JID.2015.171.","journal-title":"J Investig Dermatol"},{"issue":"4","key":"722_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/S40257-021-00598-4","volume":"22","author":"T Torres","year":"2021","unstructured":"Torres T, Puig L, Vender R, et al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567\u201379. https:\/\/doi.org\/10.1007\/S40257-021-00598-4.","journal-title":"Am J Clin Dermatol"},{"key":"722_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/FMED.2020.625755","volume":"7","author":"AI Mourad","year":"2021","unstructured":"Mourad AI, Gniadecki R. Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis. Front Med. 2021;7: 625755. https:\/\/doi.org\/10.3389\/FMED.2020.625755.","journal-title":"Front Med"},{"issue":"7","key":"722_CR7","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/J.JID.2021.01.005","volume":"141","author":"H Mehta","year":"2021","unstructured":"Mehta H, Mashiko S, Angsana J, et al. Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs secukinumab. J Investig Dermatol. 2021;141(7):1707-1718.e9. https:\/\/doi.org\/10.1016\/J.JID.2021.01.005.","journal-title":"J Investig Dermatol"},{"issue":"9","key":"722_CR8","doi-asserted-by":"publisher","first-page":"13030\/qt2qn1p4b","DOI":"10.5070\/D3249041420","volume":"24","author":"A Azevedo","year":"2018","unstructured":"Azevedo A, Torres T. The successful treatment with ixekizumab in a multi-failure psoriasis patient. Dermatol Online J. 2018;24(9):13030\/qt2qn1p4bz. https:\/\/doi.org\/10.5070\/D3249041420.","journal-title":"Dermatol Online J"},{"key":"722_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Lu J, Allan B, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39\u201350. https:\/\/doi.org\/10.2147\/JIR.S100940.","journal-title":"J Inflamm Res"},{"key":"722_CR10","doi-asserted-by":"publisher","DOI":"10.7573\/DIC.212570","volume":"8","author":"A Foulkes","year":"2019","unstructured":"Foulkes A, Warren R. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8: 212570. https:\/\/doi.org\/10.7573\/DIC.212570.","journal-title":"Drugs Context."},{"issue":"2","key":"722_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/BJD.18981","volume":"183","author":"ZZN Yiu","year":"2020","unstructured":"Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294\u2013302. https:\/\/doi.org\/10.1111\/BJD.18981.","journal-title":"Br J Dermatol"},{"issue":"1","key":"722_CR12","doi-asserted-by":"publisher","first-page":"16068","DOI":"10.1038\/S41598-018-34293-Y","volume":"8","author":"P-T Lin","year":"2018","unstructured":"Lin P-T, Wang S-H, Chi C-C. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1):16068. https:\/\/doi.org\/10.1038\/S41598-018-34293-Y.","journal-title":"Sci Rep"},{"issue":"6","key":"722_CR13","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/JDV.16180","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Jullien D, Martin A, Peralta C. Real-world evidence of secukinumab in psoriasis treatment\u2014a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34(6):1174\u201385. https:\/\/doi.org\/10.1111\/JDV.16180.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"722_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2217\/imt-2020-0040","volume":"12","author":"C L\u00f3pez-S\u00e1nchez","year":"2020","unstructured":"L\u00f3pez-S\u00e1nchez C, Puig L. Guselkumab in the treatment of moderate-to-severe plaque psoriasis. Immunotherapy. 2020;12:355\u201371. https:\/\/doi.org\/10.2217\/imt-2020-0040.","journal-title":"Immunotherapy"},{"issue":"1","key":"722_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/1346-8138.16214","volume":"49","author":"MJ Gooderham","year":"2022","unstructured":"Gooderham MJ, Lynde C, Turchin I, Avadisian M, Labelle M, Papp KA. Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. J Dermatol. 2022;49(1):95\u2013105. https:\/\/doi.org\/10.1111\/1346-8138.16214.","journal-title":"J Dermatol"},{"issue":"6","key":"722_CR16","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/S13555-021-00616-7","volume":"11","author":"M Schmitt-Egenolf","year":"2021","unstructured":"Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykowicz NM, Apol E, Hansen JB, Levin L\u00c5. Drug persistence of biologic treatments in psoriasis: a Swedish National Population Study. Dermatol Ther. 2021;11(6):2107\u201321. https:\/\/doi.org\/10.1007\/S13555-021-00616-7.","journal-title":"Dermatol Ther"},{"issue":"3","key":"722_CR17","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/BJD.20416","volume":"185","author":"H Iznardo","year":"2021","unstructured":"Iznardo H, Vilarrasa E, L\u00f3pez-Ferrer A, Puig L. Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. Br J Dermatol. 2021;185(3):660\u20132. https:\/\/doi.org\/10.1111\/BJD.20416.","journal-title":"Br J Dermatol"},{"key":"722_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2021.1961998","volume":"13","author":"P Dapavo","year":"2021","unstructured":"Dapavo P, Siliquini N, Mastorino L, et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatol Treat. 2021;13:1\u20136. https:\/\/doi.org\/10.1080\/09546634.2021.1961998.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"722_CR19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/BJD.19701","volume":"184","author":"T Graier","year":"2021","unstructured":"Graier T, Salmhofer W, Jonak C, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol. 2021;184(6):1094\u2013105. https:\/\/doi.org\/10.1111\/BJD.19701.","journal-title":"Br J Dermatol"},{"issue":"3","key":"722_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/BJD.17738","volume":"181","author":"A Mourad","year":"2019","unstructured":"Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181(3):450\u20138. https:\/\/doi.org\/10.1111\/BJD.17738.","journal-title":"Br J Dermatol"},{"issue":"7","key":"722_CR21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/JDV.12208","volume":"28","author":"JM Carrascosa","year":"2014","unstructured":"Carrascosa JM, Vilavella M, Garcia-Doval I, et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol. 2014;28(7):907\u201314. https:\/\/doi.org\/10.1111\/JDV.12208.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"722_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/J.COPH.2019.05.007","volume":"46","author":"P Gisondi","year":"2019","unstructured":"Gisondi P, Geat D, Pizzolato M, Girolomoni G. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Curr Opin Pharmacol. 2019;46:90\u20139. https:\/\/doi.org\/10.1016\/J.COPH.2019.05.007.","journal-title":"Curr Opin Pharmacol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00722-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00722-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00722-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T09:43:31Z","timestamp":1665999811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00722-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00722-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"2 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tiago Torres has received honoraria for acting as a consultant and\/or speaker for AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, and Novartis. Luis Puig has received honoraria for acting as a consultant and\/or speaker for AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi, and UCB. Ron Vender has received grants\/research support from, and\/or acted as a speaker\/consultant for AbbVie, Amgen, Arcutis, Bausch-Health, BMS, Boehringer Ingelheim, Celgene, Centocor, Dermira, Dermavant, Galderma, GSK, Innovaderm, Janssen, Kabi-Care, Leo, Lilly, Takeda, Novartis, Merck, Palladin, Pfizer, Regeneron, Sandoz, Sanofi, Sun, UCB, and Viatris-Mylan. Jensen Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GSK, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon. Jos\u00e9-Manuel Carrascosa has participated as a PI\/SI, member of steering committees, advisor, and\/or invited speaker for Celgene, Amgen, AbbVie, Almirall, Novartis, Leo-Pharma, Lilly, Sandoz, Mylan, Janssen, Boehringer Ingelheim, UCB, and BMS. Stefano Piaserico has been a consultant and\/or speaker for AbbVie, Almirall, Amgen, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. Paolo Gisondi has received honoraria for acting as a consultant and\/or speaker for AbbVie, Almirall, Amgen, Biogen, Bristol Myers Squibb, Celgene, Janssen, LEO Pharma, Eli Lilly, MSD, Novartis, Pierre Fabre, Sanofi, and UCB. Charles Lynde has been a speaker and\/or consultant for AbbVie, Altius, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Dermavant, Devonian, Eli Lilly, Fresnius Kabi, Galderma, GSK, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L'Oreal, Medexus, MedX, Merck, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, TEVA, Tribute, UCB, Valeant, Viatris, and Volo Health. Paulo Ferreira has received honoraria for acting as a consultant and\/or speaker for AbbVie, Janssen, LEO Pharma, Eli-Lilly, Novartis, and Pfizer. Pedro Mendes-Bastos has received honoraria for acting as a consultant and\/or speaker for AbbVie, Pfizer, Janssen, LEO Pharma, Novartis, Sanofi, Teva, Bayer, and L\u2019Oreal. Esteban Dauden has been an advisory board member and consultant, participated in clinical trials, and received grants, research support, and honorarium for speaking from AbbVie\/Abbott, Almirall, Amgen-Celgene, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD-Schering-Plough, Lilly, UCB, Bristol Myers, and Boehringer Ingelheim. Elena del Alcazar-Viladomiu has participated as an SI and\/or invited speaker for AbbVie, Janssen, Novartis, Lilly, Leo Pharma, Almirall, Amgen, UCB, and Sanofi. Eva Vilarrasa Rull has received honoraria for acting as a consultant and\/or speaker for AbbVie, Almirall, Boehringer, Celgene, Janssen, Leo Pharma, Eli Lilly, MSD, Novartis, Pfizer, and UCB. Mar Llamas-Velasco has received honoraria for acting as a consultant and\/or speaker for AbbVie\/Abbott, Almirall, Amgen-Celgene, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, and Lilly. Jan Hugo has received honoraria for acting as a consultant\/speaker for AbbVie, Amgen, and Novartis. Anna Balato has received honoraria for acting as speaker and consultant for Sanofi, AbbVie, and Eli Lilly. Marco Romanelli has been an advisory board member and consultant, received fees and speaker\u2019s honoraria, or participated in clinical trials for AbbVie, Abiogen, Almirall, Lilly, Mundipharma, Novartis, Leo Pharma, Smith & Nephew, Urgo Medical, Hartman, and Sanofi. Francesca Prignano has served as an advisory board member and consultant, received fees and speaker's honoraria, or participated in clinical trials for AbbVie, Almirall, Leo Pharma, Lilly, Janssen, Novartis, Biogen, and Sanofi Genzyme. Spyridon Gkalpakiotis has received honoraria for acting as a consultant and\/or speaker for AbbVie, Amgen, Eli Lilly, Novartis, Leo Pharma, and Janssen-Cilag. Curdin Conrad has served as a scientific adviser, clinical study investigator, and\/or paid speaker for AbbVie, Actelion, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung, and UCB. Elizabeth Lazaridou has received honoraria for acting as a consultant and\/or speaker for AbbVie, Eli Lilly-Galderma, Leo, Novartis, Janssen, UCB, Pfizer, Genesis Pharma, and Sanofi. Natalia Rompoti has received honoraria\u00a0for\u00a0lectures\u00a0from Janssen, AbbVie, Genesis\u00a0Pharma, Leo, Lilly Pharmaserve, Novartis, and UCB,\u00a0and\u00a0support\u00a0for scientific congress attendance\u00a0from\u00a0AbbVie, Janssen, Leo, Lilly Pharmaserve, Novartis, and UCB. Marina Papoutsaki has received honoraria for advisory boards and lectures from Janssen, Leo Pharma, MSD, Genesis Pharma, Pfizer, Novartis, AbbVie, and UCB, and support as an investigator in clinical studies from AbbVie, Novartis, Leo Pharma, and Janssen. Miguel Nogueira has received honoraria for acting as a consultant\/speaker for Abbvie and Leo Pharma. Andrea Chiricozzi has served as an advisory board member and consultant, received fees and speaker's honoraria, or participated in clinical trials for AbbVie, Almirall, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Janssen, Novartis, Sanofi Genzyme, and UCB Pharma. Luiz Leite, Joana Valerio, Federico Pirro, Francesco Messina, Manfredo Bruni, Gaetano Licata, Federica Ricceri, Alessia Nidegger, Asfandyar Mufti, Athina-Ioanna Daponte, Laetitia Teixeira have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was conducted in accordance with the Declaration of Helsinki (initially published in 1964) on Ethical Principles for Medical Research Involving Human Subjects and after approval by the local ethical committees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was waived due to the study\u2019s retrospective design. Data were properly anonymized before the analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TT and AC contributed to the study conception and design. TT, LP, LT, MN and AC conducted the statistical analyses on the data. All authors participated in data collection and interpretation of the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and were accountable for the accuracy and integrity of the article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}